Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
Silo Pharma (Nasdaq: SILO) has secured a significant patent in Australia (patent number 2020271839) for its PTSD drug candidate SPC-15. The patent, granted to Silo's research partner Columbia University, covers the invention "Prophylactic efficacy of serotonin 4 receptor agonists against stress" which is exclusively licensed to Silo.
SPC-15, the company's lead asset, is being developed as an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent strengthens Silo's global intellectual property portfolio and supports their plans for clinical trial development of this innovative therapeutic approach to preventing stress-induced disorders.
Silo Pharma (Nasdaq: SILO) ha ottenuto un importante brevetto in Australia (numero di brevetto 2020271839) per il suo candidato farmaco contro il disturbo da stress post-traumatico, SPC-15. Il brevetto, concessO al partner di ricerca di Silo, la Columbia University, riguarda l'invenzione "Efficacia profilattica degli agonisti del recettore della serotonina 4 contro lo stress" ed è concesso in licenza esclusiva a Silo.
SPC-15, il principale asset dell'azienda, è in sviluppo come trattamento intranasale mirato al disturbo da stress post-traumatico (PTSD). Il brevetto rafforza il portafoglio di proprietà intellettuale globale di Silo e sostiene i piani per lo sviluppo di studi clinici su questo approccio terapeutico innovativo volto a prevenire i disturbi indotti dallo stress.
Silo Pharma (Nasdaq: SILO) ha asegurado una patente significativa en Australia (n.º de patente 2020271839) para su candidato farmacológico para el TEPT, SPC-15. La patente, otorgada al socio de investigación de Silo, la Universidad de Columbia, cubre la invención "Eficacia profiláctica de los agonistas del receptor 4 de serotonina frente al estrés" y está licenciada en exclusiva a Silo.
SPC-15, el principal activo de la empresa, se está desarrollando como un tratamiento intranasal dirigido al trastorno por estrés postraumático (TEPT). La patente refuerza la cartera de propiedad intelectual global de Silo y respalda sus planes para el desarrollo de ensayos clínicos de este enfoque terapéutico innovador para prevenir los trastornos inducidos por el estrés.
Silo Pharma (나스닥: SILO)는 PTSD 약물 후보 SPC-15에 대해 호주에서 중요한 특허(특허 번호 2020271839)를 확보했습니다. 이 특허는 Silo의 연구 파트너인 콜럼비아 대학교에 부여되었으며, 발명 명칭은 "스트레스에 대한 세로토닌 4 수용체 작용제의 예방적 효능"으로 Silo에 독점적으로 라이선스되어 있습니다.
회사의 주력 자산인 SPC-15는 외상 후 스트레스 장애(PTSD)를 표적으로 하는 비강 투여 치료제로 개발 중입니다. 이 특허는 Silo의 글로벌 지적재산권 포트폴리오를 강화하고 스트레스 유발 장애를 예방하기 위한 이 혁신적 치료법의 임상시험 개발 계획을 뒷받침합니다.
Silo Pharma (Nasdaq: SILO) a obtenu un brevet important en Australie (numéro de brevet 2020271839) pour son candidat-médicament contre le SSPT, SPC-15. Le brevet, accordé au partenaire de recherche de Silo, la Columbia University, couvre l'invention « Efficacité prophylactique des agonistes du récepteur de la sérotonine 4 contre le stress » et est licencié en exclusivité à Silo.
SPC-15, l'actif principal de la société, est en cours de développement en tant que traitement intranasal ciblant le trouble de stress post-traumatique (TSPT). Ce brevet renforce le portefeuille mondial de propriété intellectuelle de Silo et soutient leurs plans de développement d'essais cliniques pour cette approche thérapeutique innovante visant à prévenir les troubles induits par le stress.
Silo Pharma (Nasdaq: SILO) hat in Australien (Patentsnummer 2020271839) ein bedeutendes Patent für seinen PTSD-Wirkstoffkandidaten SPC-15 gesichert. Das Patent, das dem Forschungspartner von Silo, der Columbia University, erteilt wurde, deckt die Erfindung "Prophylaktische Wirksamkeit von Agonisten des Serotonin-4-Rezeptors gegen Stress" ab und ist exklusiv an Silo lizenziert.
SPC-15, der führende Wirkstoff des Unternehmens, wird als intranasale Behandlung gegen posttraumatische Belastungsstörung (PTSD) entwickelt. Das Patent stärkt Silos globales geistiges Eigentum und unterstützt die Pläne für die klinische Entwicklung dieses innovativen therapeutischen Ansatzes zur Verhinderung stressbedingter Störungen.
- Patent granted in Australia strengthens global IP protection for SPC-15
- Exclusive licensing agreement with Columbia University for PTSD treatment
- Novel intranasal delivery method for PTSD treatment
- None.
SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University.
The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), originally developed by Columbia University.
“This patent further strengthens our global IP portfolio for SPC-15, protecting its novel approach to preventing stress-induced disorders and enhancing stress resilience,” said Silo CEO Eric Weisblum. “The claims further strengthen and support our plans for clinical trial development of SPC-15 as an innovative therapeutic for PTSD.”
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What patent did Silo Pharma (SILO) receive in Australia?
What is Silo Pharma's SPC-15 drug candidate designed to treat?
Who originally developed Silo Pharma's PTSD treatment SPC-15?
How will the Australian patent impact Silo Pharma's development plans?
What type of delivery method does Silo Pharma's PTSD treatment use?
